Elliot Norry
About
Elliot Norry is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Elliot Norry has authored 31 papers receiving a total of 371 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 20 papers in Immunology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Elliot Norry's work include CAR-T cell therapy research (26 papers), Immunotherapy and Immune Responses (20 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Elliot Norry is often cited by papers focused on CAR-T cell therapy research (26 papers), Immunotherapy and Immune Responses (20 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Elliot Norry collaborates with scholars based in United States, Spain and Canada. Elliot Norry's co-authors include Trupti Trivedi, Rafael G. Amado, Sandra P. D’Angelo, Jean‐Marc Navenot, Karen Chagin, Dennis Williams, Erin Van Winkle, Brian Andrew Van Tine, Lini Pandite and Malini Iyengar and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Elliot Norry
30 papers receiving 360 citations
Peers
Elliot Norry
Guanghai Dai China
Vincent Armenio United States
William N. Bell United States
Casilda Llácer Spain
Éléonore De Guillebon France
Xile Zhou China
Magnus Pedersen Denmark
Teppei Yamada Japan
Candy Garcia United States
Xingxing Qi China
Citations per year, relative to Elliot Norry Elliot Norry (= 1×)
peers
Guanghai Dai
Countries citing papers authored by Elliot Norry
Since
Specialization
Citations
This map shows the geographic impact of Elliot Norry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elliot Norry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elliot Norry more than expected).
Fields of papers citing papers by Elliot Norry
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Elliot Norry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elliot Norry. The network helps show where Elliot Norry may publish in the future.
Co-authorship network of co-authors of Elliot Norry
This figure shows the co-authorship network connecting the top 25 collaborators of Elliot Norry. A scholar is included among the top collaborators of Elliot Norry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elliot Norry. Elliot Norry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
D’Angelo, Sandra P., Mihaela Druta, Brian A. Van Tine, et al.. (2025). Long-Term Survival of Patients with Advanced/Metastatic Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Who Received the T-Cell Receptor T-Cell Therapy, Afamitresgene Autoleucel, in the Phase 2 Spearhead-1 Trial. Transplantation and Cellular Therapy. 31(2). S250–S250.
2.
Moore, Kathleen N., Ana Oaknin, Isabelle Ray‐Coquard, et al.. (2024). GOG-3084: A phase II trial of ADP-A2M4CD8 TCR-T cell therapy, alone or in combination with nivolumab, among patients with recurrent ovarian cancers. Gynecologic Oncology. 190. S281–S282.
3.
D’Angelo, Sandra P., Andrew Furness, Fiona Thistlethwaite, et al.. (2024). Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial.. Journal of Clinical Oncology. 42(16_suppl). 2500–2500.
4.
Aggen, David H., David S. Hong, Jeffrey Clarke, et al.. (2023). Preliminary clinical outcomes of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced urothelial cancer.. Journal of Clinical Oncology. 41(6_suppl). 517–517.
5.
Moore, Kathleen N., Ana Oaknin, Isabelle Ray‐Coquard, et al.. (2023). #24 A phase 2 study (GOG-3084) OF ADP-A2M4CD8 TCR T-cell therapy, alone or in combination with nivolumab, in patients with recurrent ovarian cancers. A407.2–A408.
6.
He, Kewen, David S. Hong, Partow Kebriaei, et al.. (2023). Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report. Melanoma Research. 33(4). 332–337.
7.
Tine, Brian Andrew Van, Kristen N. Ganjoo, Jean‐Yves Blay, et al.. (2023). The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma.. Journal of Clinical Oncology. 41(16_suppl). 11563–11563.
8.
Murphy, Mariela A. Blum, Jaffer A. Ajani, Brian Andrew Van Tine, et al.. (2023). Safety and efficacy from the phase 1 SURPASS trial of ADP-A2M4CD8, a next-generation T-cell receptor T-cell therapy, in patients with advanced esophageal, esophagogastric junction, or gastric cancer.. Journal of Clinical Oncology. 41(4_suppl). 349–349.
9.
Moore, Kathleen N., Adam Asch, Víctor Moreno, et al.. (2022). 2022-LBA-414-ESGO Preliminary clinical outcome of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced epithelial ovarian cancer. International Journal of Gynecological Cancer. 32. A472–A473.
10.
D’Angelo, Sandra P., Steven Attia, Jean‐Yves Blay, et al.. (2022). Identification of response stratification factors from pooled efficacy analyses of afamitresgene autoleucel (“Afami-cel” [Formerly ADP-A2M4]) in metastatic synovial sarcoma and myxoid/round cell liposarcoma phase 1 and phase 2 trials.. Journal of Clinical Oncology. 40(16_suppl). 11562–11562.
11.
Kim, Sang T., Jean Tayar, Siqing Fu, et al.. (2021). Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab. Journal for ImmunoTherapy of Cancer. 9(7). e002716–e002716.
12.
Stadtmauer, Edward A., Thomas Faitg, Daniel E. Lowther, et al.. (2019). Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma. Blood Advances. 3(13). 2022–2034.
13.
Goyal, Lipika, Matthew J. Frigault, Tim Meyer, et al.. (2019). Abstract 3183: Initial safety of AFP SPEAR T-cells in patients with advanced hepatocellular carcinoma. Cancer Research. 79(13_Supplement). 3183–3183.
14.
Goyal, Lipika, Matthew J. Frigault, Tim Meyer, et al.. (2019). Abstract 3183: Initial safety of AFP SPEAR T-cells in patients with advanced hepatocellular carcinoma. Immunology. 3183–3183.
15.
Sanderson, Joseph P., Thomas Weissensteiner, George R. Pope, et al.. (2018). Tuning T‐Cell Receptor Affinity to Optimize Clinical Risk‐Benefit When Targeting Alpha‐Fetoprotein–Positive Liver Cancer. Hepatology. 69(5). 2061–2075.
16.
Lam, Vincent K., David S. Hong, John V. Heymach, et al.. (2018). Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials.. Journal of Clinical Oncology. 36(15_suppl). 3056–3056.
17.
D’Angelo, Sandra P., Mihaela Druta, George D. Demetri, et al.. (2017). A pilot study of NY-ESO-1c259 T cells in subjects with advanced myxoid/round cell liposarcoma (NCT02992743).. Journal of Clinical Oncology. 35(15_suppl). TPS3097–TPS3097.
18.
Mackall, Crystal L., Sandra P. D’Angelo, Mihaela Cristea, et al.. (2016). Cytokine release syndrome (CRS) in patients treated with NY-ESO-1c259 TCR.. Journal of Clinical Oncology. 34(15_suppl). 3040–3040.
19.
Mackall, Crystal L., Sandra P. D’Angelo, Stephan A. Grupp, et al.. (2016). Autologous genetically engineered NY-ESO-1c259T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors.. Journal of Clinical Oncology. 34(15_suppl). TPS3101–TPS3101.
20.
Powles, Thomas, Sergio Bracarda, Chen Mei, et al.. (2015). Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients. European Journal of Cancer. 51(10). 1293–1302.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Guanghai Dai Breakdown of academic impact, for papers by Vincent Armenio Breakdown of academic impact, for papers by William N. Bell Breakdown of academic impact, for papers by Casilda Llácer Breakdown of academic impact, for papers by Éléonore De Guillebon Breakdown of academic impact, for papers by Xile Zhou Breakdown of academic impact, for papers by Magnus Pedersen Breakdown of academic impact, for papers by Teppei Yamada Breakdown of academic impact, for papers by Candy Garcia Breakdown of academic impact, for papers by Xingxing Qi